(Reuters photo)CU-Cov19 -- a novel coronavirus vaccine being developed by a Thai research team in collaboration with the University of Pennsylvania -- is expected to enter mass production by the end of the third quarter next year, the research team said on Sunday. The research team -- led by Kiat Ruxrungtham of the Chula Vaccine Research Centre -- made the remark at a press conference charting progress in their work. The team has been testing Cu-Cov19, an mRNA vaccine, on 13 macaques at Chulalongkorn University's National Primate Research Centre in Saraburi. The result has led to high hopes that the country can successfully produce its own vaccine against Covid-19 by the third quarter of next year. It is estimated that around two billion doses of Covid-19 vaccine will be produced by the end of next year -- which is unlikely to be enough to meet the global demand.

Source: Bangkok Post July 12, 2020 23:15 UTC